Presenting Phase 2 Trial Efficacy Data to Biotech Venture Capitalists
Biotech VCs scrutinize $p$-values, hazard ratios, and adverse event profiles. Here is how founders present trial endpoints with scientific rigor.
Vishal VermaCTO & Co-Founder, Dehurdle
May 13, 20254 min read
The Primary Endpoint Delivery Script
Recommended Spoken Script
"In our double-blind, randomized Phase 2 trial of 120 patients, our small molecule met its primary endpoint with a statistically significant 42% reduction in tumor volume ($p < 0.001$) versus standard of care. Treatment-related Grade 3 adverse events remained below 4%, providing a clean therapeutic window for our Phase 3 FDA registrational trial."
The 2-Minute Practice Drill
2-Minute Spoken Drill
The 2-Minute Practice Drill
Practice your biotech investor pitch in Dehurdle.